Turning Point Therapeutics ($TPTX) was recently acquired by BMS for a whopping $4.1 billion in cash. Turning Point’s most advanced molecule is repotrectinib, a potential best-in-class ROS1/TRK/ALK tyrosine kinase inhibitor in Ph. I/II studies for cancer. This article explores the science behind repotrectinib, one of our 2021 Molecules of the Month, what properties make it valuable, and how we know.
request a trial
Premium members get access to our library of hundreds of in-depth reviews on key molecules, ten new reviews each month, novel drug approval coverage, drug discovery company updates, and more.
Interested in learning more? Submit this form to request a trial.
